Catabasis Pharmaceuticals, Inc. (CATB) News
Filter CATB News Items
CATB News Results
|Loading, please wait...|
CATB News Highlights
- CATB's 30 day story count now stands at 4.
- Over the past 8 days, the trend for CATB's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- STAR, HAE and JILL are the most mentioned tickers in articles about CATB.
Latest CATB News From Around the Web
Below are the latest news stories about Catabasis Pharmaceuticals Inc that investors may wish to consider to help them evaluate CATB as an investment opportunity.
BOSTON, September 10, 2021--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on lead program STAR-0215 at the following upcoming virtual investor conferences:
Once-struggling, Catabasis Pharmaceuticals Inc (NASDAQ: CATB) is looking to hit the reset button with a new name and focus. Catabasis has been dragging for several years, weighed down mainly by the failure of the edasalonexent program in Duchenne muscular dystrophy. After it failed in a late-stage study, Catabasis decided to discontinue the development of the drug altogether. Then, in February, Catabasis acquired another local company, a rare disease startup called Quellis Biosciences. Now, Cata
Catabasis Pharmaceuticals Announces New Company Name, Astria Therapeutics, Highlighting New Company Focus
BOSTON, September 08, 2021--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced its new name, Astria Therapeutics, Inc. ("Astria" or the "Company"). The name Astria originates from the Greek word for star, reflecting the Company’s commitment to having patients serve as guiding stars. Astria’s mission is to bring hope with life-changing therapies to patients and families. Astria expects t
The big shareholder groups in Catabasis Pharmaceuticals, Inc. ( NASDAQ:CATB ) have power over the company. Large...
Catabasis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
BOSTON, August 09, 2021--Catabasis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
BOSTON, August 04, 2021--Catabasis Pharmaceuticals To Present At 2021 Wedbush PacGrow Healthcare Conference
BOSTON, July 07, 2021--Catabasis will present information on its lead program QLS-215 at the Ladenburg Thalmann 2021 Healthcare Conference.
U.S. stock futures were mixed on Wednesday ahead of the Federal Reserve’s policy decision, following its Federal Open Market Committee (FOMC) two-day policy meeting. Notably, investors await data for May related to housing starts and permits, along with export and import prices, which are to be released today. S&P futures remain relatively flat, while Nasdaq futures had gained about 0.1%, at the time of writing and Dow futures were trading 0.2% lower. X Financial (XYF) and Centogene NV (CNTG) are expected to report earnings before the market opens, while Lennar (LEN) and Honest Company, Inc. (HNST) are expected to report after the market close.
We're at the midpoint of the week now and we're still going strong with a look at the biggest pre-market stock movers for Wednesday.